US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PELTHOS THERAPEUTICS INC

19.39

-1.7399-8.23%

Volume:32.14K

Turnover:643.11K

Market Cap:58.84M

PE:-1.56

High:21.00

Open:20.31

Low:19.07

Close:21.13

Loading ...

Overview Company News Filings

Company Profile

Company Name:

PELTHOS THERAPEUTICS INC

Exchange:

AMEX

Establishment Date:

2002

Employees:

8

Office Location:

4020 Stirrup Creek Drive,Suite 110,Durham,North Carolina,United States

Website:

http://www.chromocell.com

Zip Code:

27703

Phone:

Fax:

- -

Introduction:

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Directors

Name

Position

Francis Knuettel II

Director,Chief Executive Officer and President, Chief Financial Officer, Treasurer and Secretary

Todd Davis

Director and Chairman of the Board

Chia Lin Simmons

Director

Ezra Friedberg

Director

Richard Malamut

Director

Shareholders

Name

Position

Francis Knuettel II

Director,Chief Executive Officer and President, Chief Financial Officer, Treasurer and Secretary

Eric Lang

Chief Medical Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PTHS/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTHS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTHS\",,,,,undefined,":{"symbol":"PTHS","market":"US","secType":"STK","nameCN":"PELTHOS THERAPEUTICS INC","latestPrice":19.3901,"timestamp":1752694670420,"preClose":21.13,"halted":0,"volume":32138,"delay":0,"floatShares":2683095,"shares":3034400,"eps":-12.40475,"marketStatus":"Trading","change":-1.7399,"latestTime":"07-16 15:38:55 EDT","open":20.31,"high":21,"low":19.07,"amount":643114.2893119999,"amplitude":0.091339,"askPrice":21,"askSize":904,"bidPrice":19.4,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-12.40475,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1752696000000},"marketStatusCode":2,"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":21.13,"preHourTrading":{"tag":"盘前","latestPrice":20.4,"preClose":21.13,"latestTime":"09:14 EDT","volume":23,"amount":468.84000399999996,"timestamp":1752671672094},"postHourTrading":{"tag":"盘后","latestPrice":20,"preClose":21.13,"latestTime":"19:52 EDT","volume":522,"amount":10548.32,"timestamp":1752623557944},"volumeRatio":0.157304},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTHS\",,,,,undefined,":{"symbol":"PTHS","floatShares":2683095,"roa":"-188.95%","roe":"--","lyrEps":-14.27101,"volumeRatio":0.157304,"shares":3034400,"dividePrice":0,"high":21,"amplitude":0.091339,"preClose":21.13,"low":19.07,"week52Low":4.5,"pbRate":"-14.02","week52High":54.29,"institutionHeld":0,"latestPrice":19.3901,"committee":-0.978118,"eps":-12.40475,"divideRate":0,"volume":32138,"delay":0,"ttmEps":-12.40475,"open":20.31,"prevYearClose":6.41,"prevWeekClose":18.32,"prevMonthClose":12.6,"prevQuarterClose":12.6,"fiveDayClose":16.47,"twentyDayClose":12.2,"sixtyDayClose":18.4},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1803540075,"yearFounded":2002,"employeeNum":8,"address":"4020 Stirrup Creek Drive,Suite 110,Durham,North Carolina,United States","zipCode":"27703","officePhone":"877 265 8266"},"stockCompanyDetail":{"websiteUrl":"http://www.chromocell.com","stockEarnings":[{"period":"1week","weight":0.0629},{"period":"1month","weight":0.7228},{"period":"3month","weight":0.6837},{"period":"6month","weight":1.201},{"period":"1year","weight":0.806},{"period":"ytd","weight":2.2964}],"compareEarnings":[{"period":"1week","weight":0.0029},{"period":"1month","weight":0.0421},{"period":"3month","weight":0.1835},{"period":"6month","weight":0.0516},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.0615}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.","exchange":"AMEX","name":"PELTHOS THERAPEUTICS INC","nameEN":"PELTHOS THERAPEUTICS INC"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PTHS\",market:\"US\",,,undefined,":{"directors":[{"name":"Francis Knuettel II","position":"Director,Chief Executive Officer and President, Chief Financial Officer, Treasurer and Secretary"},{"name":"Todd Davis","position":"Director and Chairman of the Board"},{"name":"Chia Lin Simmons","position":"Director"},{"name":"Ezra Friedberg","position":"Director"},{"name":"Richard Malamut","position":"Director"}],"executives":[{"name":"Francis Knuettel II","position":"Director,Chief Executive Officer and President, Chief Financial Officer, Treasurer and Secretary"},{"name":"Eric Lang","position":"Chief Medical Officer"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTHS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-02","symbol":"PTHS","defaultRemindTime":1751463000000,"type":"split","dateTimestamp":1751428800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTHS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTHS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PTHS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PTHS","date":"2025-07-15","current":-1.911381,"percent":0.25,"low":-2.372872,"twenty":-2.07698,"median":-1.641655,"eighty":-1.450338,"high":-1.189404,"avg":-1.733188,"sd":0.383589,"marketCap":14068948},"quantilePoints":[{"date":"2025-07-03","current":-1.450338,"twenty":-1.398151,"median":-1.319871,"eighty":-1.241591,"marketCap":10675383},{"date":"2025-07-11","current":-2.372872,"twenty":-2.216593,"median":-1.475876,"eighty":-1.450338,"marketCap":17465810},{"date":"2025-07-15","current":-1.911381,"twenty":-2.07698,"median":-1.641655,"eighty":-1.450338,"marketCap":14068948}],"updateTime":1752666770185}}}